Oxford Biomedical Research receives $730,000 grant for cancer research

Rochester Hills-based Oxford Biomedical Research is working on a new blood test that could help detect anti-cancer agents in patients.

A Small Business Innovation Research contract from the National Institute of Environmental Health Sciences is helping fund the development of this test with a contract worth nearly $730,000.

The test measures a blood-borne protein that may be a biomarker for the efficacy of anti-cancer agents. A team of scientists, led by Dr. Thomas Eling at the National Institute of Health, discovered that treatment of animals with low doses of drugs such as aspirin and ibuprofen reduce the occurrences of cancer and help produce more anti-cancer agents.

The idea behind the test is to allow doctors to monitor cancer-fighting agents and study their effectiveness. It could also help them discover new anti-cancer agents.

Oxford Biomedical Research develops, manufactures and markets more than 700 products for biomedical research. Its primary focus is on tests for oxidative stress and chronic inflammation, two major contributors to a variety of diseases.

The firm has been named as an Oakland County Emerging Sector Company. It launched a new venture called Wellness Indicators to leverage the company's 25 years of expertise

Source: Oxford Biomedical Research
Writer: Jon Zemke

Related Tags

Biotechnology, Healthcare, Oakland County, Research

Oxford Biomedical Research receives $730,000 grant for cancer research

Related Tags

Recommended Content

Across Our Network